LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma.

被引：0
|
作者：
Lee, Hans C.
Bumma, Naresh
Richter, Joshua Ryan
Dhodapkar, Madhav V.
Hoffman, James E.
Suvannasankha, Attaya
Zonder, Jeffrey A.
Shah, Mansi R.
Lentzsch, Suzanne
Maly, Joseph J.
Ye, Jing Christine
Wu, Ka Lung
DeVeaux, Michelle
Chokshi, Dhruti
Boyapati, Anita
Hazra, Anasuya
Rodriguez-Lorenc, Karen
Kroog, Glenn Scott
Houvras, Yariv J.
Jagannath, Sundar
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH USA
[3] Icahn Sch Med Mt Sinai, New York, NY USA
[4] Emory Univ, Sch Med, Atlanta, GA USA
[5] Univ Miami Hlth Syst, Miami, FL USA
[6] Indiana Univ, Simon Canc Ctr, Indianapolis, IN USA
[7] Roudebush VAMC, Indianapolis, IN USA
[8] Karmanos Canc Inst, Detroit, MI USA
[9] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[10] Columbia Univ, Med Ctr, New York, NY USA
[11] Norton Canc Inst, Louisville, KY USA
[12] Univ Michigan, Ann Arbor, MI USA
[13] Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp, Belgium
[14] Regeneron Pharmaceut Inc, Tarrytown, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8006
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
    Yee, Andrew Jenho
    Laubach, Jacob
    Campagnaro, Erica Leigh
    Lipe, Brea
    Nadeem, Omar
    Cole, Craig
    O'Donnell, Elizabeth
    Schlossman, Robert L.
    Bianchi, Giada
    Branagan, Andrew Robert
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Thorburn, Cassandra Ann
    Mann, Mason L.
    Lohr, Jens Guenter
    Richardson, Paul G.
    Raje, Noopur S.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [42] Bortezomib in patients with relapsed-refractory multiple myeloma (MM). Clinical observations.
    Kyrtsonis, MC
    Sachanas, S
    Vassilakopoulos, TP
    Kafassi, N
    Tzenou, T
    Papadogiannis, A
    Kalpadakis, C
    Antoniadis, AG
    Dimopoulou, MN
    Angelopoulou, MK
    Siakantaris, MP
    Dimitriadou, EM
    Kokoris, SI
    Plata, E
    Tsaftaridis, P
    Panayiotidis, P
    Pangalis, GA
    BLOOD, 2005, 106 (11) : 382B - 382B
  • [43] Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM)
    Lacy, Martha Q.
    LaPlant, Betsy R.
    Laumann, Kristina M.
    Kumar, Shaji
    Gertz, Morie A.
    Hayman, Suzanne R.
    Buadi, Francis
    Dispenzieri, Angela
    Lust, John A.
    Kapoor, Prashant
    Leung, Nelson
    Russell, Stephen J.
    Dingli, David
    Gonsalves, Wilson I.
    Fonseca, Rafael
    Bergsagel, P. Leif
    Roy, Vivek
    Sher, Taimur
    Ailawadhi, Sikander
    Chanan-Khan, Asher
    Stewart, A. Keith
    Reeder, Craig B.
    Rajkumar, S. Vincent
    Mikhael, Joseph R.
    BLOOD, 2014, 124 (21)
  • [44] Influence of Cytogenetics in Patients with Relapsed and Refractory Multiple Myeloma (MM) Treated with Carfilzomib (CFZ).
    Jakubowiak, Andrzej
    Wang, Luhua
    Orlowski, Robert Z.
    Jagannath, Sundar
    Siegel, David
    Stewart, A. Keith
    Kukreti, Vishal
    Lonial, Sagar
    McDonagh, Kevin T.
    Vallone, Marcy
    Kauffman, Michael
    Vij, Ravi
    BLOOD, 2009, 114 (22) : 725 - 726
  • [45] A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.
    Yee, Andrew J.
    Nadeem, Omar
    Rosenblatt, Jacalyn
    Bianchi, Giada
    O'Donnell, Elizabeth
    Branagan, Andrew R.
    Harrington, Cynthia C.
    Agyemang, Emerentia A.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Packer, Lisette A.
    Bernstein, Zachary S.
    Lyons, Rebecca T.
    Riadi, Manal
    Rowell, Sean M.
    Mcvey, Cailin
    Goguen, Amy C.
    Horick, Nora K.
    Richardson, Paul G.
    Raje, Noopur S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] Phase lb study of panobinostat in combination with lenalidomide, bortezomib, and dexamethasone in relapsed refractory multiple myeloma.
    Laubach, Jacob
    Tuchman, Sascha Alexander
    Rosenblatt, Jacalyn
    Redd, Robert
    Colson, Kathleen
    Motta, Ashley
    Fitzpatrick, Kathleen
    Weller, Edie
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [47] Content validity of the satisfaction and experience questionnaire (SEQ)-multiple myeloma (MM) among patients with relapsed/refractory multiple myeloma
    Yucel, Emre
    Skalicky, Anne
    Eseyin, Olabimpe
    Panjabi, Sumeet
    QUALITY OF LIFE RESEARCH, 2019, 28 : S86 - S87
  • [48] Phase 2, open-label study of venetoclax in combination with carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
    Bueno, Orlando
    Xu, Tu
    Cordero, Jaclyn
    Morris, Lura
    Ross, Jeremy
    Freise, Kevin
    Munasinghe, Wijith
    Leverson, Joel
    Mudd, Sarah
    Verdugo, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [49] A randomized phase II study of elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.
    Moreau, Philippe
    Richardson, Paul Gerard Guy
    Jakubowiak, Andrzej J.
    Jagannath, Sundar
    Raab, Marc
    Facon, Thierry
    Vij, Ravi
    Reece, Donna Ellen
    White, Darrell
    Benboubker, Lotfi
    Zonder, Jeffrey A.
    Rossi, Jean-Francois
    Tsao, Claire
    Parli, Teresa
    Kroog, Glenn Scott
    Singhal, Anil
    Lonial, Sagar
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] Phase I/II Study with Single Agent Everolimus (RAD001) in Patients with Relapsed or Refractory Multiple myeloma.
    Guenther, Andreas
    Baumann, Philipp
    Burger, Renate
    Klapper, Wolfram
    Schmidmaier, Ralf
    Gramatzki, Martin
    BLOOD, 2009, 114 (22) : 1481 - 1481
12345